The offer is the latest in the OxyContin maker's attempt to resolve more than 1,000 lawsuits accusing Purdue of helping fuel the opioid crisis.

“We're going to go to a marketplace where we don't have rebates,” Pfizer's Ian Read told analysts.

The move comes as the Oxycontin maker tries to overhaul its business and distance itself from the U.S. opioid crisis.

Pfizer Inc. agreed to delay implementation of planned price increases for certain drugs a day after President Donald Trump launched an attack on the company.

Trump's recent drug plan suggested looking at whether benefit managers should be considered fiduciaries, which would force them to put their customers' financial interests ahead of their own.

While Martin Shkreli became notorious for sharply increasing drug prices, this duo has quietly plied their trade helping to kick-start drug company sales.

Purdue Pharma's decision to stop promoting its opioid drugs is being hailed as the first result of a judge's push for concrete solutions to a nationwide epidemic.

Pain-pill giant Purdue Pharma LP plans to send a letter to doctors saying that its salespeople will no longer come to their clinics to talk about the companys pain products.